Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;69(5):950-956.
doi: 10.1161/HYPERTENSIONAHA.116.08952. Epub 2017 Mar 13.

Continuum of Renin-Independent Aldosteronism in Normotension

Affiliations
Free PMC article

Continuum of Renin-Independent Aldosteronism in Normotension

Rene Baudrand et al. Hypertension. 2017 May.
Free PMC article

Abstract

Primary aldosteronism is a severe form of autonomous aldosteronism. Milder forms of autonomous and renin-independent aldosteronism may be common, even in normotension. We characterized aldosterone secretion in 210 normotensives who had suppressed plasma renin activity (<1.0 ng/mL per hour), completed an oral sodium suppression test, received an infusion of angiotensin II, and had measurements of blood pressure and renal plasma flow. Continuous associations between urinary aldosterone excretion rate, renin, and potassium handling were investigated. Severe autonomous aldosterone secretion that was consistent with confirmed primary aldosteronism was defined based on accepted criteria of an aldosterone excretion rate >12 μg/24 hours with urinary sodium excretion >200 mmol/24 hours. Across the population, there were strong and significant associations between higher aldosterone excretion rate and higher urinary potassium excretion, higher angiotensin II-stimulated aldosterone, and lower plasma renin activity, suggesting a continuum of renin-independent aldosteronism and mineralocorticoid receptor activity. Autonomous aldosterone secretion that fulfilled confirmatory criteria for primary aldosteronism was detected in 29 participants (14%). Normotensives with evidence suggestive of confirmed primary aldosteronism had higher 24-hour urinary aldosterone excretion rate (20.2±12.2 versus 6.2±2.9 μg/24 hours; P<0.001) as expected, but also higher angiotensin II-stimulated aldosterone (12.4±8.6 versus 6.6±4.3 ng/dL; P<0.001) and lower 24-hour urinary sodium-to-potassium excretion (2.69±0.65 versus 3.69±1.50 mmol/mmol; P=0.001); however, there were no differences in age, aldosterone-to-renin ratio, blood pressure, or renal plasma flow between the 2 groups. These findings indicate a continuum of renin-independent aldosteronism and mineralocorticoid receptor activity in normotension that ranges from subtle to overtly dysregulated and autonomous. Longitudinal studies are needed to determine whether this spectrum of autonomous aldosterone secretion contributes to hypertension and cardiovascular disease.

Keywords: aldosterone; hypertension; normotensive; potassium; primary aldosteronism; renin.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Association between 24h urinary aldosterone excretion and the adrenal aldosterone response to an infusion of angiotensin II
Black circles represent normotensive participants without PA (24h urinary AER<12 mcg/24), red circles represent normotensive participants who fulfill the confirmatory criteria for PA (24h urinary AER≥12 mcg/24h), solid green line represents the mean regression line, and dotted green lines represent the 95% confidence intervals for the mean regression line. (AngII=angiotensin II)
Figure 2
Figure 2. Association between 24h urinary aldosterone excretion and the 24h urinary sodium-to-potassium excretion ratio
Black circles represent normotensive participants without PA (24h urinary AER<12 mcg/24), red circles represent normotensive participants who fulfill the confirmatory criteria for PA (24h urinary AER≥12 mcg/24h), solid green line represents the mean regression line, and dotted green lines represent the 95% confidence intervals for the mean regression line.
Figure 3
Figure 3. The Relationship Between Autonomous Aldosterone Secretion, Renin, and Urinary Sodium-to-Potassium Excretion
Autonomous aldosterone secretion is represented by tertiles of the 24h urinary aldosterone excretion rate measured on a liberalized dietary sodium intervention. Renin activity is represented by tertiles of renin when sodium restricted, whereby an inability to stimulate renin serves as a surrogate for excessive MR activity. The figure displays the interaction between the independent variables, aldosterone secretion and renin activity, and the dependent variable, urinary sodium-to-potassium excretion ratio. Bars represent the mean value in each tertile. The adjusted interaction model is adjusted for age, sex, race, body-mass index, and systolic blood pressure. (AER=24h aldosterone excretion rate; PRA=plasma renin activity)

Comment in

Similar articles

Cited by

  • Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism.
    Araujo-Castro M, Ruiz-Sánchez JG, Parra Ramírez P, Martín Rojas-Marcos P, Aguilera-Saborido A, Gómez Cerezo JF, López Lazareno N, Torregrosa Quesada ME, Gorrin Ramos J, Oriola J, Poch E, Oliveras A, Méndez Monter JV, Gómez Muriel I, Bella-Cueto MR, Mercader Cidoncha E, Runkle I, Hanzu FA; In representation of the following medical Spanish societies: Spanish Society of Endocrinology and Nutrition (SEEN), Spanish Society of Cardiology (SEC), Spanish Society of Nephrology (SEN), Spanish Society of Internal Medicine (SEMI), Spanish Radiology Society (SERAM), Spanish Society of Vascular and Interventional Radiology (SERVEI), Spanish Society of Laboratory Medicine (SEQC(ML), Spanish Society of Anatomic-Pathology, Spanish Association of Surgeons (AEC). Araujo-Castro M, et al. Endocrine. 2024 Mar 6. doi: 10.1007/s12020-024-03751-1. Online ahead of print. Endocrine. 2024. PMID: 38448679 Review.
  • Endocrine Hypertension: The Urgent Need for Greater Global Awareness.
    Fernandez CJ, Nagendra L, Alkhalifah M, Pappachan JM. Fernandez CJ, et al. touchREV Endocrinol. 2023 Nov;19(2):31-41. doi: 10.17925/EE.2023.19.2.11. Epub 2023 Oct 20. touchREV Endocrinol. 2023. PMID: 38187076 Free PMC article. Review.
  • Efficacy of Oral Furosemide Test for Primary Aldosteronism Diagnosis.
    Freitas TC, Maciel AAW, Fagundes GFC, Petenuci J, Santana LS, Guimaraes AG, Freitas-Castro F, Srougi V, Tanno FY, Chambo JL, Pereira MAA, Brito LP, Pio-Abreu A, Bortolotto LA, Latronico AC, Fragoso MCBV, Drager LF, Mendonca BB, Almeida MQ. Freitas TC, et al. J Endocr Soc. 2023 Nov 24;8(1):bvad147. doi: 10.1210/jendso/bvad147. eCollection 2023 Dec 1. J Endocr Soc. 2023. PMID: 38075562 Free PMC article.
  • Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study.
    Hundemer GL, Agharazii M, Madore F, Vaidya A, Brown JM, Leung AA, Kline GA, Larose E, Piché ME, Crean AM, Shaw JLV, Ramsay T, Hametner B, Wassertheurer S, Sood MM, Hiremath S, Ruzicka M, Goupil R. Hundemer GL, et al. Circulation. 2024 Jan 9;149(2):124-134. doi: 10.1161/CIRCULATIONAHA.123.066389. Epub 2023 Nov 30. Circulation. 2024. PMID: 38031887
  • Epidemiology and diagnosis of primary aldosteronism. What have we learned from the SPAIN-ALDO registry?
    Araujo-Castro M, Pascual-Corrales E, Martín Rojas P, Parra Ramírez P. Araujo-Castro M, et al. Endocrine. 2024 Mar;83(3):527-536. doi: 10.1007/s12020-023-03573-7. Epub 2023 Oct 26. Endocrine. 2024. PMID: 37884825 Review.

References

    1. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF., Jr The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism. 2016;101:1889–1916. - PubMed
    1. Xanthakis V, Vasan RS. Aldosterone and the risk of hypertension. Current Hypertension reports. 2013;15:102–107. - PMC - PubMed
    1. Wu VC, Wang SM, Chang CH, Hu YH, Lin LY, Lin YH, Chueh SC, Chen L, Wu KD. Long term outcome of aldosteronism after target treatments. Scientific Reports. 2016;6:32103. - PMC - PubMed
    1. Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: A review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. European Journal of Endocrinology. 2015;172:R191–203. - PubMed
    1. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161–165. - PubMed

Publication types